SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

14 Feb 2024 Evaluate
The December 2023 quarter revenue stood at Rs. 91.78 millions, up 16.63% as compared to Rs. 78.69 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2023 is Rs. -37.75 millions as compared to Net Loss of Rs. -32.50 millions of corresponding quarter ended December 2022 Operating profit Margin for the quarter ended December 2023 further decreased to -24.42% as compared to -23.09% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 91.78 78.69 16.63 291.19 228.18 27.61 309.87 605.25 -48.80
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.18 0.05 260.00
PBIDT -24.42 -23.09 5.76 -80.52 -48.54 65.88 -70.99 14.81 -579.34
Interest 3.64 1.98 83.84 9.99 5.47 82.63 14.87 9.25 60.76
PBDT -28.57 -28.50 0.25 -92.61 -60.81 52.29 -93.20 11.02 -945.74
Depreciation 6.88 4.00 72.00 20.22 12.00 68.50 20.52 15.91 28.98
PBT -35.45 -32.50 9.08 -112.83 -72.81 54.96 -113.72 -4.89 2225.56
TAX 2.30 0.00 0.00 2.10 0.00 0.00 1.98 1.21 63.64
Deferred Tax 2.30 0.00 0.00 2.10 0.00 0.00 1.98 1.21 63.64
PAT -37.75 -32.50 16.15 -114.93 -72.81 57.85 -115.70 -6.10 1796.72
Equity 334.84 142.01 135.79 334.84 142.01 135.79 142.01 142.01 0.00
PBIDTM(%) -26.61 -29.34 -9.32 -27.65 -21.27 29.99 -22.91 2.45 -1036.27

Oxygenta Pharma Share Price

56.06 -1.73 (-2.99%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×